Description du projet
Des traitements par ARN contre les maladies cardiométaboliques
Les maladies cardiométaboliques regroupent le diabète, la stéatose hépatique non alcoolique et les maladies cardiovasculaires athérosclérotiques. Bien que ces maladies coexistent fréquemment chez les patients, les interventions doivent encore être conçues contre leurs cibles communes et leurs voies partagées. Le projet LiverTarget, financé par l’UE, réunit des experts mondiaux dans le domaine afin de développer et de tester des thérapies innovantes contre ces maladies cardiométaboliques. Les chercheurs se concentreront sur les thérapies basées sur l’acide ribonucléique (ARN), comme les petits ARN interférents, pour neutraliser l’expression des gènes inflammatoires dans le foie. Ces molécules d’ARN seront complexées avec des nanoparticules lipidiques pour être administrées au foie, leur efficacité sera testée dans des modèles précliniques de souris, et les principaux candidats seront évalués.
Objectif
RNA Therapeutics comprise a new rapidly expanding category of drugs including small interfering RNAs (siRNA) and messenger RNAs (mRNA) that have attracted tremendous interest recently due to their first in-class drug approvals and notable success of the mRNA vaccines in the clinic.
Obesity, diabetes, non-alcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular disease (ASCVD), in turn, are highly prevalent devastating diseases of our times despite available medicines, accounting for more than one in two deaths worldwide. They frequently co-exist, in the same patient, and constitute independent risk factors for each other; yet, unified approaches directed against common targets and shared mechanisms are lacking.
LiverTarget aims at exploiting Partners years of research in the field of cardiometabolic research, the identification of ceramide pathways and inflammatory targets, and the development of novel siRNA technologies and lipid formulations, to:
1. Generate innovative siRNA pools and synthetic mRNAs to regulate ceramide and inflammatory targets in the liver.
2. Formulate them in established human-approved liver-targeting lipid nanoparticles (LNP).
3. Determine their efficacy in vivo in preclinical mouse models of obesity, diabetes, non-alcoholic fatty liver disease (NAFLD) and atherosclerosis.
4. Complete the necessary safety and toxicology evaluation of the most promising lead candidates and prepare the preclinical evaluation dossier for the European Medicines Agency (EMA).
This will result in a set of novel RNA-LNP formulations, directed against targets shared between ASCVD, diabetes and NAFLD, with demonstrated efficacy and toxicology, ready for further clinical development. It will also open up new directions of research towards the development innovative RNA therapeutics against liver targets for the treatment of cardiometabolic diseases, ultimately benefiting the patient, the society and the economy.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
33100 Tampere
Finlande